Summary by Moomoo AI
Johnson & Johnson (J&J) has announced the filing of its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Shareholders scheduled for April 25, 2024. The proxy statement details the agenda for the meeting, including the election of 13 director nominees, an advisory vote on executive officer compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2024. Additionally, two shareholder proposals are presented for consideration: one regarding gender-based compensation gaps and associated risks, and another on the impact of extended patent exclusivities on patient access. The Board of Directors has recommended voting against both shareholder proposals. The meeting will be held in a virtual format, and shareholders as of the record date, February 27, 2024, are eligible to vote. The proxy statement and annual report are available online, and shareholders are encouraged to vote in advance using the internet, phone, or mail.